Clinical Trial Comparator Supplies
180 Northolt Road,
South Harrow,
Middlesex,
HA2 0LT Other,
United Kingdom
Durbin is a specialist provider of comparator drugs for clinical trials. In addition to comparator drugs, Durbin also provides ancillary supplies and placebos. Durbin brings global sourcing expertise, transparent pricing and global custom distribution to the supply of comparators and ancillaries for clinical trials.
Durbin has over 45 years’ experience in sourcing pharmaceuticals and distributing them worldwide. Durbin combines this heritage with expertise in supplying comparators to pharmaceutical companies, both directly and via third parties, to bring a difference to the market.
Durbin buys direct from manufacturers and wholesalers. We have extensive and close relationships with all the top 30 pharmaceutical companies across Europe and North America. Sourcing from manufacturers and wholesalers guarantees pedigree and a reliable audit trail. We also supply placebos and ancillary items such as infusion pumps, non-PVC administration sets and infusions. We offer:
Durbin is committed to openness throughout the supply process. We will share with you our cost price and negotiate with you a mutually acceptable profit margin. Sourcing generically can offer up to 80% discount on branded list price. Durbin works closely with all generic companies to negotiate substantial discounts for our clients. We offer:
Durbin’s expertise in distribution ensures we can deliver clinical trial comparators to trial centres across the world, including China, Russia and India. We can deliver any amount and supply Europe within 24 hours. Having multi-lingual account managers enables us to negotiate directly with importation authorities to reduce duty payments and delays. The languages spoken by our team include Cantonese, Mandarin, Russian, Hindi, Spanish, French and German.
Benefits of our clinical trial comparator supply service include:
Durbin has built a reputation of being able to source and supply oncology, cold chain and high-value comparator drugs quickly, efficiently and at lower than normal costs. We will devise sourcing and distribution strategies to lower the costs of clinical trial supply.
Durbin has extensive contracts and partnerships with the top 30 global pharmaceutical companies and research-based biotech companies. We can advise on all areas of clinical trial supply and logistics.
Alofisel® (formerly Cx601 / darvadstrocel) is the first allogeneic stem cell therapy to be approved for the treatment of complex perianal fistulas in adult patients with Crohn’s disease.
Zinbryta (daclizumab) is an injectable formulation jointly developed by Biogen and Abbive for the treatment of relapsing forms of multiple sclerosis (MS) in adults.
Herzuma® (trastuzumab biosimilar / CT-P6) is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer.
Biktarvy® is a once-daily regimen indicated for the treatment of HIV-1 infection in adults that were previously not treated with anti-retroviral medicines.
Bevyxxa (betrixaban) is a drug developed by Portola Pharmaceuticals that is indicated for the prevention and treatment of venous thromboembolism (VTE) in adults.
Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma (STS) in adult patients. The drug is available as a 10mg/ml injection.
Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above.
Zejula™ (niraparib) is a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor approved for the treatment of adult patients with ovarian cancer.
Translarna™ (ataluren) is a protein restoration therapy indicated for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The drug was developed by PTC Therapeutics.
Formerly known as LEE011, Kisqali® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer in post-menopausal women.
180 Northolt Road
South Harrow
Middlesex
HA2 0LT
Other
United Kingdom
© Copyright Verdict Media Limited 2021
